Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Enhanced machine learning models for predicting three-year mortality in Non-STEMI patients aged 75 and above.BMC geriatrics · 2025
   Article
2. Association between body mass index and three-year outcome of acute myocardial infarction.Scientific reports · 2024
   Article
3. Mortality prognosis of NGAL, NTproBNP, hsTnT, and GRACE score in patients with acute coronary syndrome.International journal of cardiology. Heart & vasculature · 2024
   Article
4. Age-related outcomes in patients with cardiogenic shock stratified by etiology.Journal of geriatric cardiology : JGC · 2023
   Article
5. Predictors of Readmission after the First Acute Coronary Syndrome and the Risk of Recurrent Cardiovascular Events-Seven Years of Patient Follow-Up.Life (Basel, Switzerland) · 2023
   Article
6. Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review.Interventional cardiology (London, England) · 2023
   Review
7. A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.Medical science monitor : international medical journal of experimental and clinical research · 2022
   Review
8. A cardiac arrest on a spiked helmet electrocardiographic sign in anterior leads in a patient with a diagnosis of acute myocardial infarction: A case report.Annals of medicine and surgery (2012) · 2022
   Article
9. [52/f-Acute chest pain : Preparation for the medical specialist examination: part 93].Der Internist · 2021
   Article
10. Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event.BMJ case reports · 2021
    Article
11. Value of ACEF-II Score in Predicting Major Adverse Cardiac Events in Patients With Non-ST-Segment Elevation Myocardial Infarction and Unstable Angina.Texas Heart Institute journal
    Article
12. Usefulness of the Quick-Sepsis Organ Failure Assessment Score in Cardiovascular Intensive Care Unit to Predict Prognosis in Acute Coronary Syndrome.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article

Corrections and comments

• Erratum for
  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.2021

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.